ResMed Stock (NYSE:RMD), Trade Ideas

ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Long Ideas

News

Penny Stocks

Small Cap

Markets

Media

Trading Ideas

AMZN

ILMN

NVDA

SMCI

UBER

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended buying  Uber Technologies, Inc.  (NYSE: UBER).

Jim Cramer Isn&#39;t Going With This Tech Company: &#39;It&#39;s Complicated. I&#39;m A Nvidia Guy&#39;

Price Target

Pre-Market Outlook

Analyst Ratings

BIIB

CVLG

DECK

INTU

ISRG

TSLA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

AT&amp;T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

Large Cap

Health Care

General

ResMed (NYSE: RMD) recalls certain respiratory masks with magnets due to potential interference with medical devices. FDA Class I recall.

FDA Identifies ResMed&#39;s Recall Of Certain Ventilator Device Masks With Magnets As Most Serious

ResMed Inc

Remedy Entertainment PLC

Richmond Minerals Inc

RICHMOND MINERALS INC by Richmond Minerals Inc.

WIIM

ResMed shares are trading higher after the stock fell last week on sleep apnea data from Lilly.

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>ResMed</strong>.</p>
<p>Looking at options history for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $316,230 and 4, calls, for a total amount of $287,536.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $195.0 for ResMed over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ResMed's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ResMed's whale trades within a strike price range from $170.0 to $195.0 in the last 30 days. </p>
<h3>ResMed Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713361567_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$8.5</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$175.00</td>
<td>$112.8K</td>
<td style="text-align: right;">812</td>
<td style="text-align: right;">192</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$11.0</td>
<td>$8.3</td>
<td>$9.8</td>
<td>$175.00</td>
<td>$98.0K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$4.2</td>
<td>$3.8</td>
<td>$4.1</td>
<td>$170.00</td>
<td>$79.9K</td>
<td style="text-align: right;">396</td>
<td style="text-align: right;">111</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$9.4</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$195.00</td>
<td>$72.8K</td>
<td style="text-align: right;">65</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$11.2</td>
<td>$8.9</td>
<td>$10.3</td>
<td>$175.00</td>
<td>$61.8K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ResMed</h3>
<p>ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.</p>
<p>Following our analysis of the options activities associated with ResMed, we pivot to a closer look at the company's own performance.</p>
<h3>ResMed's Current Market Status</h3>
<ul>
<li>With a volume of 211,966, the price of RMD is down -3.27% at $178.82. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for ResMed</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $219.5.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Mizuho keeps a Buy rating on ResMed with a target price of $215. </li>
<li>An analyst from Needham has decided to maintain their Buy rating on ResMed, which currently sits at a price target of $224. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ResMed with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

ResMed Unusual Options Activity For April 17

ResMed shares are trading lower following positive sleep apnea data from Eli Lilly, which could cause potential competitive pressures for ResMed.

<p>ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 16.58%. Currently, ResMed has a market capitalization of $27.51 billion. </p>
<p><strong>Buying $1000 In RMD:</strong> If an investor had bought $1000 of RMD stock 15 years ago, it would be worth <strong>$10,104.11</strong> today based on a price of $187.00 for RMD at the time of writing.</p>
<h3>ResMed's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713196823_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years

<p>On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; <strong>Jim Cramer</strong> recommended buying <strong> Uber Technologies, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>). &quot;I think Uber is <a href="https://www.benzinga.com/markets/equities/24/04/38110358/whats-going-on-with-uber-technologies-shares-friday">really well run,&quot; he noted</a>.</p>
<p>Uber&nbsp;recently entered into a new nationwide partnership with&nbsp;<strong>The Vitamin Shoppe</strong>, bringing the New Jersey-based health and wellness retailer&rsquo;s selection to the Uber Eats app.</p>
<p>When asked about <strong> Citigroup Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>), he said, &quot;I feel better about Citi than I have in a long time, but that doesn&rsquo;t mean I&rsquo;m not in favor of <strong>Wells Fargo</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wfc#NYSE">WFC</a>).&quot;</p>
<p><strong>Illumina</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) is &quot;no good,&quot; Cramer said, &ldquo;You want <strong>Danaher</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dhr#NYSE">DHR</a>), same business, better company.&quot;</p>
<p>Cramer likes <strong> Amazon.com, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>), too.</p>
<p><strong>Academy Sports and Outdoors, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aso#NASDAQ">ASO</a>) is just &quot;not compelling to me,&quot; Cramer said.</p>
<p>The &quot;Mad Money&quot; host said he is ok with <strong> ResMed Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>). &quot;I think the stock&rsquo;s been knocked down because of the GLP-1s, and they&rsquo;ve got very good management,&quot; he added.</p>
<p>Cramer said he is ok with <strong> Brookfield Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bn#NYSE">BN</a>).</p>
<p><strong>Super Micro Computer, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) is &quot;complicated because you know I am an <strong>Nvidia</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) guy, hold it, don&rsquo;t trade it. I am not going to go with SMCI because that&rsquo;s the not as good Nvidia,&quot; Cramer said.</p>
<p>Cramer said &quot;no&quot; to <strong> BlackBerry Limited </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>).</p>
<h3><strong>Price Action:</strong></h3>
<ul>
<li>Amazon shares gained 2.8% to settle at $185.07 on Friday.</li>
<li>Illumina shares rose 1.4% to close at $127.75 during Friday&rsquo;s session.</li>
<li>Shares of Uber gained 3% to close at $77.16 on Friday.</li>
<li>Academy Sports and Outdoors shares gained 1.1% to settle at $63.45.</li>
<li>Brookfield shares gained 0.6% to settle at $40.32 during Friday&rsquo;s session.</li>
<li>Citigroup shares gained 1.1% to close at $61.60.</li>
<li>ResMed shares gained 2% to settle at $188.76 on Friday.</li>
<li>Super Micro Computer shares fell 1% to close at $948.02 during Friday&rsquo;s session.</li>
<li>BlackBerry shares fell 2.1% to settle at $2.82.</li>
</ul>
<p><em>Read Next:</em> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38087713/over-1m-bet-on-this-industrial-stock-check-out-these-4-stocks-insiders-are-buying"><em> Over $1M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying </em></a></p>
<p><em>Image: Shutterstock</em></p>


Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'

<p>Needham  analyst Mike Matson   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Buy and raises the price target from $215 to $224.</p>


Needham Maintains Buy on ResMed, Raises Price Target to $224

<p>ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 15.88%. Currently, ResMed has a market capitalization of $29.13 billion. </p>
<p><strong>Buying $1000 In RMD:</strong> If an investor had bought $1000 of RMD stock 10 years ago, it would be worth <strong>$4,377.32</strong> today based on a price of $198.03 for RMD at the time of writing.</p>
<h3>ResMed's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711657822_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today

<p>Across the recent three months, 9 analysts have shared their insights on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $203.22, accompanied by a high estimate of $227.00 and a low estimate of $180.00. This current average reflects an increase of 10.52% from the previous average price target of $183.88. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711562434_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of ResMed among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Buy</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$227.00</td>
<td>-</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Saul Hadassin</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Low</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ResMed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ResMed's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ResMed analyst ratings.</strong></a></p>
<h2>Delving into ResMed's Background</h2>
<p>ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.</p>
<h3>ResMed: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining ResMed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>12.48%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> ResMed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>17.96%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ResMed's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.78%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.06%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.31</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: ResMed Through The Eyes Of 9 Analysts

<p>Mizuho  analyst Anthony Petrone   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Buy and maintains $215 price target.</p>


Mizuho Maintains Buy on ResMed, Maintains $215 Price Target

<p><strong>ResMed's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) short percent of float has risen 4.07% since its last report. The company recently reported that it has <strong>6.58 million shares sold short</strong>, which is 5.11% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 8.16 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>ResMed Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711472414_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for ResMed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing ResMed's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ResMed's peer group average for short interest as a percentage of float is 4.14%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into ResMed's Recent Short Interest

<p>Financial giants have made a conspicuous bullish move on ResMed. Our analysis of options history for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $221,503, and 3 were calls, valued at $214,313.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $175.0 to $220.0 for ResMed during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ResMed's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ResMed's substantial trades, within a strike price spectrum from $175.0 to $220.0 over the preceding 30 days.</p>
<h3>ResMed Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709823670_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$220.00</td>
<td>$107.0K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">155</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$220.00</td>
<td>$80.7K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/19/24</td>
<td>$175.00</td>
<td>$60.3K</td>
<td style="text-align: right;">618</td>
<td style="text-align: right;">144</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$175.00</td>
<td>$46.0K</td>
<td style="text-align: right;">618</td>
<td style="text-align: right;">234</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$175.00</td>
<td>$45.1K</td>
<td style="text-align: right;">618</td>
<td style="text-align: right;">510</td>
</tr>
</tbody>
</table>
</p>
<h3>About ResMed</h3>
<p>ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.</p>
<p>Following our analysis of the options activities associated with ResMed, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is ResMed Standing Right Now?</h3>
<ul>
<li>With a volume of 109,977, the price of RMD is up 2.65% at $189.16. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 49 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ResMed options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At ResMed's Recent Unusual Options Activity

<p>Keybanc  analyst Brett Fishbin   initiates coverage on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Overweight rating and announces Price Target of $227.</p>


Initiation

Keybanc Initiates Coverage On ResMed with Overweight Rating, Announces Price Target of $227

<p>ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) has outperformed the market over the past 15 years by 3.62% on an annualized basis producing an average annual return of 15.8%. Currently, ResMed has a market capitalization of $28.43 billion. </p>
<p><strong>Buying $100 In RMD:</strong> If an investor had bought $100 of RMD stock 15 years ago, it would be worth <strong>$961.83</strong> today based on a price of $193.28 for RMD at the time of writing.</p>
<h3>ResMed's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1706817620_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


<p>Oppenheimer  analyst Suraj Kalia   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Outperform and raises the price target from $185 to $205.</p>


Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $205

<p>Mizuho  analyst Anthony Petrone   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Buy and raises the price target from $195 to $215.</p>


Mizuho Maintains Buy on ResMed, Raises Price Target to $215

<p>Mizuho  analyst Anthony Petrone   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Buy and raises the price target from $180 to $195.</p>


Mizuho Maintains Buy on ResMed, Raises Price Target to $195

<p>UBS  analyst Saul Hadassin   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral and raises the price target from $175 to $180.</p>


UBS Maintains Neutral on ResMed, Raises Price Target to $180

<p>Across the recent three months, 4 analysts have shared their insights on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $188.0, a high estimate of $215.00, and a low estimate of $160.00. Marking an increase of 7.28%, the current average surpasses the previous average price target of $175.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1706205639_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of ResMed among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Low</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ResMed. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ResMed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for ResMed's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ResMed's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ResMed analyst ratings.</strong></a></p>
<h2>Delving into ResMed's Background</h2>
<p>ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.</p>
<h3>Understanding the Numbers: ResMed's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> ResMed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately <strong>16.0%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>19.91%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ResMed's ROE excels beyond industry benchmarks, reaching <strong>5.24%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.35</strong>, ResMed adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For ResMed

<p>RBC Capital  analyst Craig Wong-Pan   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $181 to $182.</p>


RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $182

ResMed shares are trading higher after the company reported better-than-expected Q2 financial results.

Mizuho sees ResMed as "overwhelming beneficiary" of Philips consent decree

Mizuho sees ResMed as 'overwhelming beneficiary' of Philips consent decree

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InMode (INMD – Research Report), Resmed (RMD – Resea...

Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)

Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

In a report released today, Lyanne Harrison from Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), with a price...

Resmed Stock Poised for Growth: Buy Rating Affirmed Amid Revenue Upswing and Margin Expansion

Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder

BTTR, ICCM and SXTC among pre-market losers

Inspire Medical rebounds as J.P. Morgan defends after Lilly sleep data

ADSK

AILE

AORT

ASML

ATEC

ATRC

AUUD

AZTA

BTTR

CNMD

ENOV

FWBI

GKOS

HRMY

HUBC

ICCM

INDO

INGN

INMD

INSP

IRTC

JAZZ

JBHT

KIDS

LGVN

LIVN

MRNA

NARI

NONOF

RXST

SAGE

SIBN

SRDX

SXTC

URBN

VCYT

XRAY

YYAI

Press Releases

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024

Earnings

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

MatrixCare Forges Strategic Partnership with Tranzion, a Subsidiary of NHC, to Expand EHR Services for Senior Living Medical Providers

MatrixCare Earns Three 2024 Best in KLAS Awards

ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed's Smallest Full-Face CPAP Mask